Johnson & Johnson (JNJ) Shares Bought by Whittier Trust Co.

Whittier Trust Co. grew its holdings in Johnson & Johnson (NYSE:JNJ) by 4.1% during the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 377,574 shares of the company’s stock after acquiring an additional 14,978 shares during the period. Johnson & Johnson comprises approximately 2.0% of Whittier Trust Co.’s holdings, making the stock its 5th biggest holding. Whittier Trust Co.’s holdings in Johnson & Johnson were worth $39,501,000 as of its most recent SEC filing.

Several other hedge funds have also modified their holdings of the company. Financial Gravity Wealth Inc. acquired a new stake in Johnson & Johnson during the 1st quarter valued at $105,000. FNY Investment Advisers LLC acquired a new stake in Johnson & Johnson during the 2nd quarter valued at $117,000. Princeton Capital Management LLC acquired a new stake in Johnson & Johnson during the 1st quarter valued at $141,000. Smart Portfolios LLC acquired a new stake in Johnson & Johnson during the 1st quarter valued at $150,000. Finally, Live Your Vision LLC grew its holdings in Johnson & Johnson by 58.3% during the 2nd quarter. Live Your Vision LLC now owns 1,363 shares of the company’s stock valued at $172,000 after purchasing an additional 502 shares in the last quarter. 66.67% of the stock is currently owned by institutional investors and hedge funds.

In other Johnson & Johnson news, COO Michael E. Sneed sold 29,000 shares of the firm’s stock in a transaction on Monday, August 27th. The shares were sold at an average price of $134.80, for a total transaction of $3,909,200.00. Following the completion of the transaction, the chief operating officer now directly owns 59,124 shares of the company’s stock, valued at approximately $7,969,915.20. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, CAO Ronald A. Kapusta sold 7,899 shares of the firm’s stock in a transaction on Friday, September 7th. The stock was sold at an average price of $137.18, for a total transaction of $1,083,584.82. Following the transaction, the chief accounting officer now directly owns 25,725 shares of the company’s stock, valued at $3,528,955.50. The disclosure for this sale can be found here. 0.22% of the stock is owned by company insiders.

Shares of JNJ stock opened at $133.87 on Friday. The firm has a market cap of $370.70 billion, a price-to-earnings ratio of 18.34, a P/E/G ratio of 2.19 and a beta of 0.70. The company has a quick ratio of 1.33, a current ratio of 1.65 and a debt-to-equity ratio of 0.47. Johnson & Johnson has a 1-year low of $118.62 and a 1-year high of $148.32.

Johnson & Johnson (NYSE:JNJ) last announced its quarterly earnings data on Tuesday, July 17th. The company reported $2.10 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $2.06 by $0.04. The company had revenue of $20.83 billion during the quarter, compared to analyst estimates of $20.39 billion. Johnson & Johnson had a net margin of 1.70% and a return on equity of 32.79%. The firm’s revenue for the quarter was up 10.6% compared to the same quarter last year. During the same period last year, the business earned $1.83 EPS. Equities analysts forecast that Johnson & Johnson will post 8.14 earnings per share for the current fiscal year.

A number of research firms recently weighed in on JNJ. Jefferies Financial Group set a $145.00 price target on shares of Johnson & Johnson and gave the company a “buy” rating in a report on Sunday, July 15th. Sanford C. Bernstein began coverage on shares of Johnson & Johnson in a report on Wednesday, June 27th. They set a “market perform” rating and a $129.00 price target for the company. ValuEngine raised shares of Johnson & Johnson from a “sell” rating to a “hold” rating in a report on Saturday, July 28th. Wells Fargo & Co reaffirmed an “outperform” rating and set a $160.00 price target on shares of Johnson & Johnson in a report on Friday, September 14th. Finally, Goldman Sachs Group raised shares of Johnson & Johnson from a “sell” rating to a “neutral” rating in a report on Thursday, July 12th. Two analysts have rated the stock with a sell rating, nine have issued a hold rating and nine have assigned a buy rating to the stock. The stock presently has a consensus rating of “Hold” and an average target price of $143.91.

Johnson & Johnson Company Profile

Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the health care field worldwide. Its Consumer segment offers baby care products under the JOHNSON'S brand; oral care products under the LISTERINE brand; beauty products under the AVEENO, CLEAN & CLEAR, DABAO, JOHNSON'S Adult, LE PETITE MARSEILLAIS, NEUTROGENA, RoC, and OGX brands; over-the-counter medicines, including acetaminophen products under the TYLENOL brand; cold, flu, and allergy products under the SUDAFED brand; allergy products under the BENADRYL and ZYRTEC brands; ibuprofen products under the MOTRIN IB brand; and acid reflux products under the PEPCID brand.

Featured Article: Google Finance Portfolio

Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ).

Institutional Ownership by Quarter for Johnson & Johnson (NYSE:JNJ)

Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply